HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MSTR
Strategy Inc
There isn't enough reported data to score MSTR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MSTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
MSTR's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MSTR PE Valuation
MSTR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MSTR Forward outlook
There aren't enough analyst estimates for MSTR to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over MSTR on earnings, with more consistent year-over-year improvement.
MSTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$57.71 | -374% |
| Q2 2026 | -$94.04 | -960% |
| Q1 2026 | -$36.99 | -$14.75 |
| Q4 2025 | -$15.23 | -$9.17 |
| Q3 2025 | $21.07 | +$23.35 |
| Q2 2025 | $10.93 | +$12.50 |
| Q1 2025 | -$22.24 | -$21.39 |
| Q4 2024 | -$6.06 | -330% |
MSTR has swung to a loss: it lost $57.71 per share over the past year, after a profit the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MSTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MSTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $125.4M | -2.5% |
| Q2 2026 | $122.4M | +6.9% |
| Q1 2026 | $124.3M | +12% |
| Q4 2025 | $123M | +1.9% |
| Q3 2025 | $128.7M | +11% |
| Q2 2025 | $114.5M | +2.7% |
| Q1 2025 | $111.1M | -3.6% |
| Q4 2024 | $120.7M | -3% |
MSTR's revenue has picked up after five years of holding roughly level: $125M last quarter, down 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16671% | +13648 points |
| Q2 2026 | -6808% | -19064 points |
| Q1 2026 | -11642% | -6310 points |
| Q4 2025 | -14185% | -13343 points |
| Q3 2025 | 3023% | +3396 points |
| Q2 2025 | 12256% | +12436 points |
| Q1 2025 | -5331% | -5155 points |
| Q4 2024 | -842% | -808 points |
MSTR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MSTR on cash generation, producing positive trailing cash flow while its opponent burns cash.
MSTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4M | +$15.1M |
| Q2 2026 | -$5.9M | +$31.1M |
| Q1 2026 | $13M | +$18.2M |
| Q4 2025 | -$22.2M | -$4.6M |
| Q3 2025 | -$11.1M | +$30.3M |
| Q2 2025 | -$37M | -$13M |
| Q1 2025 | -$5.1M | -119% |
| Q4 2024 | -$17.6M | -2204% |
MSTR has burned cash in six of the last eight quarters: −$11M over the past year, against −$71M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MSTR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MSTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +75.5M shares |
| 1 year | +36% | +113M shares |
| 3 years | +201% | +286M shares |
| 5 years | +328% | +328M shares |
| Available history | +314% | +325M shares |
MSTR has 428M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $744,000 |
| Q3 2020 | $60.6M |
| Q2 2020 | $11.1M |
| Q1 2020 | $50.7M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MSTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.2x | Healthy |
| Q3 2020 | -5.2x | Net Cash |
| Q2 2020 | -11.9x | Net Cash |
| Q1 2020 | -17.1x | Net Cash |
| Q4 2019 | -29.1x | Net Cash |
MSTR's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MSTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 42.1 | Neutral |
MSTR's weekly RSI is 42 (neutral) and its Stochastic is 42 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MSTR PE vs Technology Sector
| Metric | MSTR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
MSTR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MSTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.2 | 19% below |
| 20 week MA | $123.6 | 7.4% below |
| 50 week MA | $138.1 | 17% below |
| 100 week MA | $235.9 | 52% below |
| 200 week MA | $168.2 | 32% below |
MSTR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MSTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.5 | $32.3 | +123% |
| 2021 | $32.3 | $59.7 | +85% |
| 2022 | $59.7 | $16.3 | -73% |
| 2023 | $16.3 | $63.2 | +288% |
| 2024 | $63.2 | $330.0 | +422% |
| 2025 | $330.0 | $158.8 | -52% |
| 2026 YTD | $158.8 | $114.4 | -28% |
MSTR has the edge over HIMS on returns for 2026, with the stronger performance.